Last updated: March 13, 2026
What is NDC 60687-0556?
The drug with National Drug Code (NDC) 60687-0556 is Ocrevus (ocrelizumab). It is marketed by Genentech, a Roche subsidiary, for the treatment of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
Market Size and Treatment Adoption
Target Population
- Multiple Sclerosis (MS): Approximately 2.8 million people globally.
- Primary Progressive MS (PPMS): Accounts for 10-15% of MS cases.
- US Patient Estimate: Approximately 400,000 MS patients; about 50,000 with PPMS.
Market Penetration
- Ocrevus launched in 2017, quickly gaining significant market share.
- Currently, Ocrevus holds roughly 60-70% of the U.S. anti-CD20 therapy market.
- Growth driven by its efficacy in both relapsing-remitting MS (RRMS) and PPMS.
Competitive Landscape
| Drug |
Company |
Indication |
Market Share (US) |
Approved Since |
| Ocrevus |
Roche |
RRMS, PPMS |
60-70% |
2017 |
| Mavenclad |
Genentech |
RRMS |
10-15% |
2019 |
| Tysabri |
Biogen |
RRMS, SPMS |
10-12% |
2004 |
| Kesimpta |
Novartis |
RRMS |
5-10% |
2020 |
Market Drivers
- Growing prevalence of MS.
- Patient preference for less frequent dosing (Ocrevus is administered biannually).
- Expanding indication approval for PPMS in 2017.
Pricing and Revenue Analysis
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $7,500 per 300 mg dose.
- Typical regimen: Two doses initially, then every six months.
- Annual treatment cost: Around $85,000 (per patient).
Revenue Estimates
- US Market: Estimated sales of approximately $2.2 billion in 2022.
- Global Market: Estimated at $3.5 billion, with growth potential in Europe and emerging markets.
Price Projections
| Year |
Estimated US Price per Year |
Notes |
| 2023 |
$85,000 |
Current level, stable pricing. |
| 2024 |
$86,000 |
Slight increase anticipated due to inflation and market dynamics. |
| 2025 |
$87,000 |
Potential for price adjustments based on payer negotiations. |
Factors Impacting Prices
- Biosimilar competition unlikely within the next 3-5 years due to high development costs, complex manufacturing, and patent protections.
- Price pressures from payers are moderate due to Ocrevus's market dominance.
- Regulatory and formulary negotiations might limit future list price increases.
Regulatory and Patent Landscape
Patent Status
- Key patents expire between 2029-2030.
- Patent litigations may delay biosimilar entry.
Regulatory Developments
- Ocrevus received approval for additional indications, including pediatric MS and later for secondary progressive MS.
- Additional biosimilars are under development but face high entry barriers.
Future Market Trends
- Expanding Indications: Ocrevus's approval for more MS subtypes and potentially other autoimmune diseases could expand its market.
- Pricing Strategies: Roche may explore value-based pricing or patient assistance programs to sustain market share.
- Biosimilar Impact: Biosimilars are unlikely to significantly impact prices within the next 3-5 years.
Summary
Ocrevus (NDC 60687-0556) remains a leading treatment for MS, with stable market position and high treatment costs. Price projections remain steady, with minimal downward pressure expected imminently. Market expansion hinges on broadening indications and maintaining patent protections.
Key Takeaways
- Ocrevus dominates the US MS treatment landscape, with a 60-70% market share.
- Annual revenue estimated at $2.2 billion in the US.
- Current list price is around $85,000 annually, with slight increases anticipated.
- Biosimilar competition is unlikely to impact prices before 2029.
- Expansion into additional indications could influence long-term market growth.
FAQs
1. When will biosimilars for Ocrevus enter the market?
Biosimilar development is underway, but significant market entry is unlikely before 2029 due to patent protections and high development costs.
2. How does Ocrevus compare to other MS therapies in pricing?
Ocrevus's annual cost, approximately $85,000, is comparable or slightly higher than other high-efficacy MS drugs like Tysabri and Kesimpta, but its dosing schedule provides convenience.
3. What are the main factors driving Ocrevus sales growth?
Growing MS prevalence, expanding approved indications, and patient preference for less frequent dosing.
4. What future regulatory approvals could impact Ocrevus's market?
Approval for additional MS subtypes, including secondary progressive MS, could expand the patient population and revenue.
5. How might pricing strategies evolve?
Roche may leverage value-based pricing, patient assistance, or formulary negotiations to sustain revenue amid competitive pressures.
Citations:
[1] IQVIA. (2022). Market Intelligence Reports.
[2] FDA. (2017). Ocrevus (ocrelizumab) approval letter.
[3] Genentech. (2023). Ocrevus prescribing information.
[4] Center for Drug Evaluation and Research. (2022). MS drug market analysis.
[5] Pharmapprove. (2022). Biosimilar development pipelines.
